Abciximab: Clinical Trials

12 trials of Abciximab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 terminated, 2 unknown. 12 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 6, Terminated 4, Unknown 2
Phase 21Unknown 1

Follow Abciximab: new trials by email Literature Review of Abciximab trials Research Report on Abciximab

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Intracoronary Abciximab With Clearway Catheter
Intracoronary bolus wtih ClearWayâ„¢RX catheter, IV abciximab - Acute Myocardial Infarction
Phase 3TerminatedGennaro Sardella1502009-06-012013-01-04
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)
Abciximab, Eptifibatide - Infarction, Myocardial
Phase 3CompletedGlaxoSmithKline4292006-10-012012-11-27
Abciximab in Wake-up Stroke
Abciximab - Stroke
Phase 3TerminatedUniversity of Zurich502005-03-012007-05-03
Myocardial Infarction With ST-Elevation
Abciximab, Abciximab placebo - Myocardial Infarction
Phase 3UnknownUniversity Hospital, Strasbourg, France2922005-01-012009-09-17
Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis
Abciximab - Stroke, Stenosis
Phase 3TerminatedUniversity of Zurich1002004-04-012007-05-03
A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)
Abciximab - Cerebrovascular Accident, Brain Ischemia
Phase 3TerminatedCentocor, Inc.8082003-10-012011-05-17
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
abciximab placebo; reteplase placebo, abciximab, abciximab, Abciximab; reteplase; abciximab placebo; abciximab, abciximab; reteplase placebo; abciximab placebo; abciximab - Myocardial Infarction
Phase 3CompletedCentocor, Inc.24612002-08-012014-07-31
Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease
Balloon Angioplasty, ReoPro - Arterial Occlusive Diseases
Phase 2 / Phase 3UnknownUniversity Hospital Tuebingen4202002-01-012006-09-12
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Full dose TNK-tPA, Half dose TNK-tPA, Heparin - Myocardial Infarction
Phase 3CompletedBoehringer Ingelheim59892000-05-012014-07-14
A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
Placebo, Heparin, Abciximab - Angioplasty, Transluminal, Percutaneous Coronary
Phase 3CompletedCentocor, Inc.27921995-02-012015-05-25
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
Abciximab, Placebo - Angina, Unstable, Angioplasty, Transluminal, Percutaneous Coronary
Phase 3CompletedCentocor, Inc.12651993-05-012015-05-25
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty
Abciximab, Placebo - Angina, Unstable, Angioplasty, Transluminal, Percutaneous Coronary
Phase 3CompletedCentocor, Inc.20381991-11-012015-06-02

Conditions studied

Myocardial Infarction (4)  ·  Ischemic Stroke (3)  ·  Stroke (3)  ·  Angina, Unstable (2)  ·  Acute Disease (1)  ·  Arterial Occlusive Diseases (1)  ·  Brain Ischemia (1)  ·  Carotid Stenosis (1)  ·  Constriction, Pathologic (1)  ·  Intracranial Hemorrhages (1)  ·  Peripheral Vascular Diseases (1)  ·  ST Elevation Myocardial Infarction (1)

Sponsors

Centocor, Inc. (5)  ·  University of Zurich (2)  ·  Boehringer Ingelheim (1)  ·  Gennaro Sardella (1)  ·  GlaxoSmithKline (1)  ·  University Hospital Tuebingen (1)  ·  University Hospital, Strasbourg, France (1)

Countries

Germany (4)  ·  France (3)  ·  Switzerland (3)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Romania (1)

Top investigators

Ralf W. Baumgartner, MD (2)  ·  Gunnar Tepe, MD (1)  ·  Iris Baumgartner, MD (1)  ·  Mario Siebler, MD (1)

Results publications

PMID 10208997, PMID 11113041, PMID 15077099, PMID 18032739, PMID 18499565, PMID 19850248, PMID 19850249, PMID 19918189, PMID 20170878, PMID 20670755, PMID 22319064, PMID 8121459, PMID 9164316, PMID 9182212, PMID 9256222